Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM149PT | TNBC | Basal B | PS-1145 | IKK | NFKB | 7530.065 | uM | inf | inf | 0.9426 | 0.9426 | 0.0000 | 0.0488 | 0.0000 | 2.0424 | |
| MDA-MB-415 | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 7512.095 | uM | inf | inf | 0.8257 | 0.8257 | 0.0000 | 0.0736 | 0.0000 | 0.8452 | |
| MDA-MB-157 | TNBC | Basal B | FTase Inhibitor I | Ftase | MAPK | 12594.167 | uM | inf | inf | 1.0079 | 1.0079 | 0.0000 | 0.0099 | 0.0000 | 1.4099 | |
| HCC38 | TNBC | Basal B | FTase Inhibitor I | Ftase | MAPK | 11850.154 | uM | inf | inf | 0.9670 | 0.9670 | 0.0000 | 0.0493 | 0.0000 | 1.9115 | |
| CAMA-1 | HR+ | Luminal | Sulindac sulfide | COX1/2 | COX | 10473.136 | uM | inf | inf | 0.9598 | 0.9598 | 0.0000 | 0.0241 | 0.0000 | 1.3186 | |
| HCC1806 | TNBC | Basal A | PS-1145 | IKK | NFKB | 7450.065 | uM | inf | inf | 1.0181 | 1.0181 | 0.0000 | 0.0205 | 0.0000 | 2.4231 | |
| HCC38 | TNBC | Basal B | FTase Inhibitor I | Ftase | MAPK | 10578.142 | uM | inf | inf | 0.9333 | 0.9333 | 0.0000 | 0.0825 | 0.0000 | 1.8112 | |
| HCC70 | TNBC | Basal A | FTase Inhibitor I | Ftase | MAPK | 12400.167 | uM | inf | inf | 1.0329 | 1.0329 | 0.0000 | 0.0088 | 0.0000 | 1.2627 | |
| MDA-MB-134-VI | HR+ | Luminal | Bosutinib | Src | nRTK | 10998.145 | uM | inf | inf | 0.7397 | 0.7397 | 0.0000 | 0.2181 | 0.0000 | 0.9403 | |
| 600MPE | HR+ | Luminal | PS-1145 | IKK | NFKB | 5898.065 | uM | inf | inf | 0.9898 | 0.9898 | 0.0000 | 0.1430 | 0.0000 | 0.6845 | |
| HCC3153 | TNBC | Basal A | PD184352 | MEK | MAPK | 10937.155 | uM | inf | inf | 0.8699 | 0.8699 | 0.0000 | 0.0994 | 0.0000 | 1.3142 | |
| HCC2185 | TNBC | Luminal | Ribavirin | 15306.211 | uM | inf | inf | 0.9179 | 0.9179 | 0.0000 | 0.0789 | 0.0000 | 0.4935 | |||
| HCC38 | TNBC | Basal B | PD184352 | MEK | MAPK | 11850.155 | uM | inf | inf | 0.9060 | 0.9060 | 0.0000 | 0.0877 | 0.0000 | 2.1810 | |
| SK-BR-3 | HER2amp | Luminal | FTase Inhibitor I | Ftase | MAPK | 11851.154 | uM | inf | inf | 0.9971 | 0.9971 | 0.0000 | 0.0156 | 0.0000 | 1.1765 | |
| MDA-MB-134-VI | HR+ | Luminal | Methotrexate | DHFR | Metabolism | 7494.084 | uM | inf | inf | 0.8665 | 0.8665 | 0.0000 | 0.1150 | 0.0000 | 1.0275 | |
| HCC1937 | TNBC | Basal A | Nilotinib | ABL | nRTK | 11849.145 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0324 | 0.0000 | 1.5253 | |
| HCC38 | TNBC | Basal B | PD184352 | MEK | MAPK | 11850.155 | uM | inf | inf | 0.9060 | 0.9060 | 0.0000 | 0.0877 | 0.0000 | 2.1810 | |
| MDA-MB-361 | HER2amp | Luminal | PS-1145 | IKK | NFKB | 7508.065 | uM | inf | inf | 1.0103 | 1.0103 | 0.0000 | 0.0104 | 0.0000 | 0.7854 | |
| BT-474 | HER2amp | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 5906.095 | uM | inf | inf | 1.0129 | 1.0129 | 0.0000 | 0.0481 | 0.0000 | 0.6731 | |
| MDA-MB-453 | TNBC | Luminal | TCS PIM-1 1 | Pim kinase | PIM | 12414.135 | uM | inf | inf | 1.0132 | 1.0132 | 0.0000 | 0.0212 | 0.0000 | 1.1872 | |
| SK-BR-3 | HER2amp | Luminal | Nilotinib | ABL | nRTK | 11851.145 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0487 | 0.0000 | 1.4873 | |
| MCF7 | HR+ | Luminal | PS-1145 | IKK | NFKB | 7492.065 | uM | inf | inf | 0.9681 | 0.9681 | 0.0000 | 0.0052 | 0.0000 | 1.6050 | |
| HCC1937 | TNBC | Basal A | FTase Inhibitor I | Ftase | MAPK | 11849.154 | uM | inf | inf | 0.9386 | 0.9386 | 0.0000 | 0.0392 | 0.0000 | 1.1927 |